General
Preferred name
LACOSAMIDE
Synonyms
Erlosamide ()
ERLOSAMIDE ()
Lacosamide ()
Lacosamide cv ()
ADD 243037 ()
ADD-243037 ()
Vimpat ()
(r)-lacosamide 1 ()
SPM 927 ()
SPM-927 ()
Lacosamide-d3 ()
P&D ID
PD009314
CAS
175481-36-4
175481-26-2
1217689-95-6
Tags
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
2008
Drug Status
approved
Drug indication
Convulsion
Diabetic neuropathy
Epilepsy
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Lacosamide is a functionalized amino acid anticonvulsant drug . (GtoPdb)
Compound Sets
22
Axon Medchem Screening Library
Cayman Chemical Bioactives
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
External IDs
39
Properties
(calculated by RDKit )
Molecular Weight
250.13
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
6
Ring Count
1
Aromatic Ring Count
1
cLogP
0.45
TPSA
67.43
Fraction CSP3
0.38
Chiral centers
1.0
Largest ring
6.0
QED
0.77
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
MOA
voltage-gated sodium channel blocker
NMDA Glycine-Site Antagonists
Sodium Channel Blockers
Target
Sodium channel alpha subunit
Na+ channel blocker
Member status
virtual
Therapeutic Class
Analgesics
VGSC Target
Nav1.5
Nav1.7
Nav1.8
Source data